

Application No.: 10/829,432  
Docket No.: BB1167USCNT

Page 3

**REMARKS**


Claims 16-20 are pending. As suggested on Page 4 of the outstanding Final Office Action, Claim 16 is hereby amended to take independent form, including the limitations of Claim 12, now canceled, and replaces "comprising" with "consisting of". Claim 16 represents the sole independent claim.

In response to the request for clarification made by the Patent Office on page 2 of the outstanding Final Office Action, Applicants confirm most of the assessment made by the Patent Office. In sum, the sequencing error eliminated nucleotide "A" at position 369<sup>1</sup> of SEQ ID NO:3, and SEQ ID NO:3 does correspond or translate to amino acid sequence SEQ ID NO:4.

In light of the present amendments, the outstanding rejections are now moot. Applicants respectfully submit that the pending claims are in condition for allowance and request an earlier indication of the same.

Please charge any fees or credit any overpayment of fees, which are required in connection herewith to Deposit Account No. 04-1928 (E.I. du Pont de Nemours and Company).

Respectfully submitted,



Thomas S. Kim  
ATTORNEY FOR APPLICANTS  
REGISTRATION NO. 51,009  
TELEPHONE: 302-992-4061  
FACSIMILE: 302-892-1026

Dated: 8/17/06

<sup>1</sup> On page 2 of the Final Office Action, the Examiner actually cites to position 379 of SEQ ID NO:3, when it actually is position 369. Still, this position correlates to position 406 of clone p0016ctscj40rb.seq.